LifeStance Reports Strong Financial Performance in Q2 2025
LifeStance Health Group, Inc. (NASDAQ: LFST), a leading provider of outpatient mental healthcare across the United States, has showcased its robust growth with the release of its financial results for the second quarter of 2025. This period witnessed LifeStance achieving remarkable revenue growth alongside significant improvements in operational metrics.
Key Financial Highlights for Q2 2025
As compared to the prior year's quarter, LifeStance reported a revenue increase of 11%, totaling $345.3 million, up from $312.3 million. This growth was significantly driven by an increase in visit volumes and clinician base expansion.
Details of Q2 2025 Performance
Among the highlights of this quarter, LifeStance achieved:
- An 11% growth in the clinician base, reaching 7,708 clinicians with a net addition of 173 in the second quarter.
- A 12% rise in visit volumes, totaling 2.2 million visits.
- A net loss of $3.8 million, a considerable reduction compared to last year’s loss of $23.3 million.
- Net cash flow from operations of $64.4 million during the second quarter.
- An adjusted EBITDA of $34.0 million, an increase of 19% from the previous year’s $28.6 million.
- Positive free cash flow of $56.6 million, marking the company's highest cash flow to date in any quarter.
Outlook for Fiscal Year 2025
LifeStance is optimistic about the upcoming quarters, reiterating its full year revenue forecast between $1.40 billion and $1.44 billion. The company also raised its Center Margin expectations to a range of $441 million to $465 million and adjusted its EBITDA guidance to a range of $140 million to $150 million.
CEO Commentary
Dave Bourdon, the CEO of LifeStance, expressed pride in the team’s achievements, highlighting the strategic growth in clinician numbers and exceptional free cash flow, enabling more investments in business initiatives.
Strong Positioning and Future Prospects
Looking ahead, LifeStance is well-positioned within the mental healthcare space. The foundation established in Q2 2025, through clinician growth and operational efficiency, showcases the company’s potential for continued success and stability in a competitive market. With increasing demand for outpatient mental healthcare, LifeStance's commitment to enhancing access and affordability remains central to its mission.
Investor Relations Contact
For additional inquiries or further information, please reach out to:
Monica Prokocki
VP of Finance & Investor Relations
602-767-2100
investor.relations@lifestance.com
Frequently Asked Questions
What is LifeStance Health Group's primary business focus?
LifeStance is one of the largest providers of outpatient mental healthcare in the U.S., offering services to children, adolescents, and adults facing various mental health conditions.
What were the total revenues reported for Q2 2025?
The company reported total revenues of $345.3 million for the second quarter of 2025.
How has the clinician base changed recently?
The clinician base grew by 11%, totaling 7,708 clinicians with a net increase of 173 in the second quarter.
What adjustments have been made to financial expectations for the fiscal year?
LifeStance has raised its full-year revenue expectations to between $1.40 billion and $1.44 billion for 2025.
How can investors reach out for more information?
Interested investors can contact Monica Prokocki, VP of Finance & Investor Relations at 602-767-2100 or email investor.relations@lifestance.com.
